Sanofi withdraws FDA application for lixisenatide

09/13/2013 | Reuters · PharmaTimes (U.K.)

Sanofi said it has pulled its application to market the diabetes drug lixisenatide in the U.S., stressing that the withdrawal was "not related to safety issues or deficiencies in the new drug application." The firm said it plans to refile the application in 2015 following a cardiovascular trial. Disclosure of interim data could affect the outcome of the trial, Sanofi said.

View Full Article in:

Reuters · PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY